Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00193076 · ClinicalTrials.gov registry record · Phase 2
Combination Gemcitabine, Carboplatin With or Without Trastuzumab in Patients With Metastatic Breast Cancer
A Phase 2 study, sponsored by SCRI Development Innovations.
- Completed
- Registry status
- Phase 2
- Development phase
- 96
- Enrollment target
NCT00193076 is a Phase 2 study that has completed, run by SCRI Development Innovations. The registered enrollment target is 96 participants.
The verdict
NCT00193076, a Phase 2 study, has completed, sponsored by SCRI Development Innovations.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 96 participants
- Enrollment target
Study Summary
Pre-clinical data suggests that combination therapy with gemcitabine and carboplatin is synergistic, and both drugs may be synergistic with trastuzumab. Additionally, recent clinical data suggest that the combination of gemcitabine with platinum is an active regimen in metastatic breast cancer. This study will test the combination of gemcitabine with carboplatin in patients with metastatic breast cancer. Patients with Her2/neu overexpression will be stratified to receive trastuzumab in addition to gemcitabine and carboplatin.
Interventions
- DRUG Trastuzumab
- DRUG Carboplatin
- DRUG Gemcitabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 96 participants |
| Start Date | 2003-11 |
| Est. Completion | 2008-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00193076
The ClinicalTrials.gov registry entry for NCT00193076 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 96 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SCRI Development Innovations, which has 146 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Trastuzumab is the first listed.
NCT00193076 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00193076 about?
NCT00193076 is a clinical study titled "Combination Gemcitabine, Carboplatin With or Without Trastuzumab in Patients With Metastatic Breast Cancer". Pre-clinical data suggests that combination therapy with gemcitabine and carboplatin is synergistic, and both drugs may be synergistic with trastuzumab. Additionally, recent clinical data suggest that the combination of gemcitabine with platinum is an active regimen in metastatic breast cancer. This...
What is the current status of trial NCT00193076?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 96 participants. The study started on 2003-11. Estimated completion is 2008-10.
What interventions are being tested in trial NCT00193076?
The interventions under investigation include: Trastuzumab (DRUG), Carboplatin (DRUG), Gemcitabine (DRUG).
Who is sponsoring clinical trial NCT00193076?
This trial is sponsored by SCRI Development Innovations, which has 146 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.